Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free
分子別名（Synonym）
DDPAC,FTDP-17,MAPT,MSTD,MTBT1,Tau,PHF-tau,TAU
表達區(qū)間及表達系統(tǒng)（Source）
Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free (TAU-H5113) is expressed from E. coli cells. It contains AA Gln 244 - Glu 372 (Accession # P10636-8 (P301L)).
Predicted N-terminus: Met
蛋白結構（Molecular Characterization）
This protein carries no "tag".
The protein has a calculated MW of 13.8 kDa.
應用說明（Application）
THT, cell assay, drug screening and other in vitro experiment.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Supplied as 0.2 μm filtered solution in PBS, pH7.4.
Contact us for customized product form or formulation.
運輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product should be stored at -70°C or room temperature for short storage. Do not store fibrils on ice or at 4°C;
The unsonicated fibril is validated to be stable after storage at -70°C for 1 year under sterile conditions;
The sonicated fibril should be stored at -70°C for not more than 8 weeks.
背景（Background）
Tau is a microtubule-associated protein, which encodes by the MAPT gene that located on chromosome 17q21. Tau Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. Hyperphosphorylation of the tau protein (tau inclusions, pTau) can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease, frontotemporal dementia, and other tauopathies. Tau-441 is known as "2N4R," "Isoform Tau-F," "Tau-4" or "Tau 441", which consisting of 441 amino acid. Tau-441 is a potential therapeutic target for pathogenesis.
關鍵字： Tau441;Tau441蛋白;Tau441重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。